2Q26 First Look: $0.20 Beat; 3% PPNR Upside on Lower Op. Exp. & Stronger NII

Research evidence excerpt

2Q26 First Look: $0.20 Beat; 3% PPNR Upside on Lower Op. Exp. & Stronger NII

om/researchdisclosures. Stock ratings and/or stock coverage may be suspended from time to time in the event that there is no

active analyst opinion or analyst coverage, but the opinion or coverage is expected to resume. Research reports and ratings should not be relied

upon as individual investment advice. As always, an investor’s decision to buy or sell a security must depend on individual circumstances, including

existing holdings, time horizons and risk tolerance. Piper Sandler sales and trading personnel may provide written or oral commentary, trade ideas, or

other information about a particular stock to clients or internal trading desks reflecting different opinions than those expressed by the research analyst.

Piper Sandler will buy and sell securities of the subject company on a principal basis, regardless of whether it is a registered market maker in those

securities. In addition, Piper Sandler offers technical research products that are based on different methodologies, may contradict the opinions contained

in fundamental research reports, and could impact the price of the subject security. Recommendations based on technical analysis are intended for the

professional trader, while fundamental opinions are typically suited for the longer-term institutional investor.

Overweight (OW): Anticipated to outperform relative to the median of the group of stocks covered by the analyst.

Neutral (N): Anticipated to perform in line relative to the median of the group of stocks covered by the analyst.

Underweight (UW): Anticipated to underperform relative to the median of the group of stocks covered by the analyst.

Other Important Information